Trastuzumab in its 150 mg single-dose lyophilized presentation is not processed into tablet, capsule, or granule dosage forms; no pharmacopoeial monograph supports oral solid administration because the intact IgG1 is denatured and cleaved by gastric acid and pepsin before reaching systemic circulation. The injectable route is therefore the only validated downstream format at this strength. The formulation composition recorded in the approved product documentation combines 150 mg trastuzumab with 136.2 mg α,α-trehalose dihydrate, 3.36 mg L-histidine hydrochloride monohydrate, 2.16 mg L-histidine, and 0.60 mg polysorbate 20; reconstitution with 7.2 mL Sterile Water for Injection yields a nominal 21 mg/mL solution at a pH of approximately 6.0. Compliance for this presentation includes sterility testing under USP <71> and Ph. Eur. 2.6.1, bacterial endotoxin testing under USP <85> and Ph. Eur. 2.6.14, subvisible particulate testing under USP <787> and Ph. Eur. 2.9.19, visible particulate inspection under USP <790>, and parenteral quality testing under USP <1>. Batch-to-batch variability in the CHO-derived glycan profile is controlled under ICH Q6B release specifications and ICH Q5E comparability when a manufacturing change is introduced; the release panel also includes size-exclusion chromatography for aggregate content, capillary electrophoresis for purity, and cell-based potency testing calibrated against the international reference standard. The manufacturing sequence begins with CHO-derived bulk drug substance that is buffer-exchanged by tangential flow filtration into a histidine-trehalose formulation buffer, passed through a 0.22 μm sterilizing-grade filter, aseptically filled into Type I glass vials, partially stoppered, and lyophilized. The lyophilization cycle is product-specific: the amorphous trehalose matrix suppresses crystallization and maintains the protein’s native structure, while the primary-drying shelf temperature is governed by the collapse temperature of the formulation; full chamber-pressure and shelf-temperature ramps are not public for commercial product, but the cycle is validated against residual moisture by Karl Fischer titration and against cake appearance by visual inspection. The terminal dosage form is a white to pale yellow lyophilized powder for concentrate for solution for infusion. The reconstituted single-dose vial contains no preservative, and the approved in-use statement limits storage to 24 hours at 2–8 °C; from a microbiological standpoint it is therefore expected to be transferred directly to an infusion bag without intermediate pooling. Refreezing the reconstituted solution is not supported by stability data.

How Does a 21 mg/mL Reconstituted Solution Remain Microbiologically Stable Across a 28-Day Multi-Dose Window?

At the 440 mg strength, the multi-dose lyophilized vial achieves the same nominal 21 mg/mL reconstituted protein concentration but differs in preservative-containing diluent and excipient mass ratios. The dry formulation combines 440 mg trastuzumab with 400 mg α,α-trehalose dihydrate, 9.9 mg L-histidine hydrochloride monohydrate, 6.4 mg L-histidine, and 1.8 mg polysorbate 20. Reconstitution with 20 mL Bacteriostatic Water for Injection containing 1.1% benzyl alcohol yields 21 mg/mL trastuzumab. The preserved system is qualified for antimicrobial effectiveness under USP <51>; the benzyl alcohol content triggers a label contraindication for use in neonates, infants, and populations with known benzyl alcohol toxicity risk. The filling line for the multi-dose format is configured to maintain a headspace and closure geometry that tolerates repeated needle puncture without loss of container closure integrity, and closure integrity is validated according to USP <1207> or an equivalent deterministic package integrity method. In manufacturing, the bulk formulation process remains aseptic: buffer exchange into the histidine-trehalose-polysorbate 20 matrix, 0.22 μm filtration, aseptic filling, and lyophilization; the multi-dose container requires additional stability and integrity studies because the in-use period extends to 28 days at 2–8 °C after reconstitution. The terminal presentation is a 440 mg lyophilized powder for concentrate for solution for infusion, intended for repeated withdrawal from a single vial in a controlled oncology pharmacy setting. Withdrawal precision is governed by the nominal 21 mg/mL concentration; institutional dose rounding is an in-use policy decision outside the API manufacturer’s control.

Subcutaneous administration requires a formulation distinct from the intravenous lyophilized presentations: a ready-to-use solution containing 600 mg trastuzumab and 10,000 U hyaluronidase-oysk in 5 mL, corresponding to 120 mg/mL antibody and 2,000 U/mL hyaluronidase. The excipient system includes L-histidine, L-histidine hydrochloride monohydrate, α,α-trehalose dihydrate, L-methionine, and polysorbate 20; the formulation is filled as a single-dose vial without preservative. The approved dosing schedule is 600 mg injected subcutaneously over 2–5 minutes every 3 weeks, and the label warns that this product must not be administered intravenously. The applicable compliance framework includes USP <1>, USP <71>, USP <85>, USP <787>, USP <790>, Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, and Ph. Eur. 2.9.19. The downstream manufacturing route concentrates the CHO-derived bulk drug substance by ultrafiltration/diafiltration to 120 mg/mL, introduces polysorbate 20 and methionine as stabilizers, and then mixes the solution with hyaluronidase-oysk under low-shear conditions; the order of excipient addition is controlled because the enzyme is less robust than the antibody and can be damaged by high interfacial stress. The fill line uses positive-displacement piston pumps and larger-diameter fluid paths to limit shear-induced aggregation and subvisible particle formation at high protein concentration. The finished article is a 5 mL single-dose vial containing a clear to opalescent solution for subcutaneous injection; because no preservative is present, any unused portion is discarded, and the vial is not suitable for multi-dose withdrawal.

When Trastuzumab Is Processed as the Antibody Intermediate for Maytansinoid Antibody-Drug Conjugates

If the intent is maytansinoid antibody-drug conjugate production, trastuzumab API is first buffer-exchanged into a conjugation buffer and then partially reduced at interchain disulfide bonds using tris(2-carboxyethyl)phosphine or dithiothreitol under controlled pH and temperature; the number of generated free sulfhydryls determines the final conjugation stoichiometry. The reduced antibody is reacted with a molar excess of the SMCC-DM1 reagent, then the conjugate is purified by tangential flow filtration and size-exclusion chromatography to remove unconjugated linker-payload, organic solvent, and high-molecular-weight aggregate. The drug-to-antibody ratio is quantified by ultraviolet/visible absorbance deconvolution and orthogonal chromatography; the approved conjugate product documentation reports a target average DAR of approximately 3.5, while the precise lot-release interval is proprietary. Batch-to-batch variability in the conjugation reaction is controlled by in-process DAR and residual free payload limits, typically measured by reversed-phase HPLC. After conjugation, the bulk is buffer-exchanged into sodium succinate buffer with sucrose and polysorbate 20, aseptically filtered through a 0.22 μm membrane, filled, and lyophilized. Compliance for this route must include ICH Q6B for conjugated protein specifications, ICH Q3D for elemental impurities because residual metals from the reduction or conjugation step may be present, ICH Q3C for residual solvents from the linker-payload preparation, and ICH Q5A(R2) for viral safety of the biological intermediate. The finished conjugate is a 100 mg or 160 mg single-dose lyophilized powder; after reconstitution with Sterile Water for Injection the nominal concentration is 20 mg/mL ado-trastuzumab emtansine. This product is not considered equivalent to unconjugated trastuzumab; dose conversion, infusion rate, and toxicity monitoring follow the conjugate label, not the unconjugated antibody label.

Use Only 0.9% Sodium Chloride for Centralized Intravenous Admixture; Dextrose and Parenteral Nutrition Are Incompatible

Once the lyophilized or liquid drug product reaches a hospital or centralized oncology pharmacy, the final downstream operation is the preparation of the patient-specific infusion. The approved labeling instructs transfer of the calculated dose into a 250 mL 0.9% Sodium Chloride Injection, USP polyvinyl chloride or polyolefin infusion bag; dextrose 5% solution is specifically contraindicated because exposure to dextrose-containing diluents has been associated with increased protein aggregation and particle formation. The diluted admixture is not preserved and is assigned an in-use storage limit of 24 hours at 2–8 °C. Administration is by intravenous infusion over 30–90 minutes through a 0.22 μm inline filter; the label prohibits intravenous push or bolus injection. Compounding staff handle the admixture under USP <797> for sterile preparation and USP <800> for hazardous drug containment because trastuzumab carries embryo-fetal toxicity warnings; closed system transfer devices, negative-pressure compounding areas, and leak-tight containers are required by that hazard assessment. The dose schedule is weight-based: the approved label specifies a loading dose of 4 mg/kg followed by weekly 2 mg/kg for the weekly intravenous regimen, and a loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks for the three-weekly regimen in the approved metastatic gastric cancer indication. Terminal point of the admixture chain is a ready-to-infuse 250 mL sodium chloride bag containing a patient-specific trastuzumab dose; no other drug should be added to the same bag, and the final infusion must be visually inspected for particulates and discoloration before administration.